Lantheus Faces FDA Setback for LNTH-2501 NDA Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 26 2026
0mins
Source: Newsfilter
- FDA Complete Response Letter: Lantheus's NDA for LNTH-2501 was not approved by the June 29, 2026 PDUFA date due to unresolved issues at a third-party manufacturing facility, highlighting compliance challenges that could delay market entry.
- No Data Concerns: The CRL did not raise any issues regarding the data submitted or the safety and efficacy of LNTH-2501, indicating that the clinical potential of the product remains recognized, which may bolster confidence for future applications.
- Management Confidence: CEO Mary Anne Heino expressed strong confidence in LNTH-2501 and commitment to resolving manufacturing issues promptly, a positive stance that could help stabilize investor sentiment amid regulatory setbacks.
- Market Impact: The delay in LNTH-2501's launch, as a diagnostic tool for neuroendocrine tumors, may affect Lantheus's market share in an increasingly competitive radiopharmaceutical landscape, emphasizing the need for swift resolution of regulatory hurdles.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LNTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LNTH
Wall Street analysts forecast LNTH stock price to fall
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 108.960
Low
70.00
Averages
82.17
High
105.00
Current: 108.960
Low
70.00
Averages
82.17
High
105.00
About LNTH
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. Its product categories include oncology, neurology, cardiology, and strategic partnerships and others. Its products include PYLARIFY, Neuraceq, and DEFINITY. PYLARIFY TruVu is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated serum prostate-specific antigen (PSA). Neuraceq is an Alzheimer's disease radiodiagnostic. Its commercial products are used by cardiologists, internists, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists across a range of clinical care settings. Its diagnostic products provide information that enables healthcare professionals (HCPs) to better detect, characterize, or rule out diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lantheus Receives FDA Complete Response Letter for LNTH-2501
- FDA Response Letter: Lantheus has received a Complete Response Letter from the FDA regarding LNTH-2501, indicating that the drug has encountered issues in the approval process, which may delay its market entry and expose the company to sales risk.
- Sales Outlook Adjustment: William Blair has pushed back the sales outlook for Octevy by one year, reflecting a decrease in market demand expectations for the product, which could negatively impact Lantheus's overall revenue growth.
- Market Reaction: The receipt of the FDA response letter may lead to a negative impact on Lantheus's stock price, raising investor concerns about the company's future profitability and resulting in a decline in market confidence.
- Strategic Implications: The delay in LNTH-2501's approval may force Lantheus to reassess its product portfolio and market strategy to address potential financial pressures and changes in the competitive landscape.
See More
Lantheus Receives Complete Response Letter from FDA for LNTH-2501
- FDA Response Letter: The US FDA issued a Complete Response Letter to Lantheus regarding LNTH-2501, stating that the application cannot be approved due to ongoing issues at a third-party manufacturing site, although no issues were noted with the supporting data, indicating the clinical data still holds potential.
- Manufacturing Issues: Lantheus CEO Mary Anne Heinosaid mentioned that the company is working closely with its partner and the FDA to address facility-related conditions, demonstrating a proactive approach to resolving the issues and advancing the program.
- Market Reaction: Despite the FDA challenges, Lantheus reiterated its 2026 revenue outlook of $1.4 billion to $1.45 billion, reflecting confidence in future performance, particularly during the transition period for the PYLARIFY TRUVU product.
- Strategic Adjustments: Lantheus showcased its turnaround progress at the Global Healthcare Conference, and despite regulatory hurdles, the company is evaluating potential sale opportunities, indicating its ability to adapt to market changes.
See More
Lantheus Faces FDA Setback for LNTH-2501 NDA Approval
- FDA Complete Response Letter: Lantheus's NDA for LNTH-2501 was not approved by the June 29, 2026 PDUFA date due to unresolved issues at a third-party manufacturing facility, highlighting compliance challenges that could delay market entry.
- No Data Concerns: The CRL did not raise any issues regarding the data submitted or the safety and efficacy of LNTH-2501, indicating that the clinical potential of the product remains recognized, which may bolster confidence for future applications.
- Management Confidence: CEO Mary Anne Heino expressed strong confidence in LNTH-2501 and commitment to resolving manufacturing issues promptly, a positive stance that could help stabilize investor sentiment amid regulatory setbacks.
- Market Impact: The delay in LNTH-2501's launch, as a diagnostic tool for neuroendocrine tumors, may affect Lantheus's market share in an increasingly competitive radiopharmaceutical landscape, emphasizing the need for swift resolution of regulatory hurdles.
See More
Lantheus Holdings Stock Surpasses Analyst Target Price
- Price Target Surpassed: Lantheus Holdings Inc (Ticker: LNTH) shares have surpassed the average analyst 12-month target price of $105.17, currently trading at $106.20, indicating optimistic market sentiment regarding the company's prospects.
- Diverse Analyst Reactions: Among the 12 analysts covered by Zacks, target prices range from $76.00 to $117.00, with a standard deviation of $11.892, reflecting varying perspectives on the company's valuation that could influence investor decisions.
- Clear Investor Signal: The stock's rise above the average target price provides a strong signal for investors to reassess the company, prompting them to consider whether the current valuation is justified or if it’s time to take profits.
- Wisdom of the Crowd: The average analyst target price embodies the
See More
Lantheus to Speak at Growth Stock Conference
- Conference Participation: John Wiggins, Vice President of External Manufacturing at Lantheus Holdings, will participate in a fireside chat at the William Blair 46th Annual Growth Stock Conference on June 3, showcasing the company's leadership in the radiopharmaceutical sector.
- Live Webcast: The live session is scheduled to begin at 12:10 p.m. ET, allowing investors to access the presentation through the Investors section of the company's website, ensuring transparent communication of key information.
- Replay Availability: A replay of the webcast will be available on the company's website for at least 30 days post-event, providing crucial insights for investors who cannot attend live, thereby enhancing investor relations.
- Company Background: Lantheus has been dedicated to radiopharmaceutical solutions for 70 years, focusing on enabling clinicians to Find, Fight, and Follow disease, ultimately improving patient outcomes.
See More
Lantheus Weighs Sale Following $7 Billion Curium Offer
- Acquisition Proposal: Lantheus Holdings is considering a takeover offer from Curium Pharma valued at approximately $7 billion, indicating strong market interest in its nuclear medicine business and potentially prompting a strategic overhaul.
- Negotiation Progress: The two companies are in discussions about a potential deal that could materialize in weeks, although no final decision has been made, reflecting uncertainty about Lantheus's future in the market.
- Market Reaction: Lantheus shares fell nearly 2% in after-hours trading, yet they have surged 54.8% this year, indicating investor confidence in its long-term growth potential despite short-term volatility.
- Valuation Insight: With a current market capitalization of about $6.15 billion, the acquisition proposal's valuation underscores Lantheus's competitiveness in the radiopharmaceutical sector, potentially attracting further investor interest in its future trajectory.
See More
Lantheus Receives FDA Complete Response Letter for LNTH-2501
- FDA Response Letter: Lantheus has received a Complete Response Letter from the FDA regarding LNTH-2501, indicating that the drug has encountered issues in the approval process, which may delay its market entry and expose the company to sales risk.
- Sales Outlook Adjustment: William Blair has pushed back the sales outlook for Octevy by one year, reflecting a decrease in market demand expectations for the product, which could negatively impact Lantheus's overall revenue growth.
- Market Reaction: The receipt of the FDA response letter may lead to a negative impact on Lantheus's stock price, raising investor concerns about the company's future profitability and resulting in a decline in market confidence.
- Strategic Implications: The delay in LNTH-2501's approval may force Lantheus to reassess its product portfolio and market strategy to address potential financial pressures and changes in the competitive landscape.
See More
Lantheus Receives Complete Response Letter from FDA for LNTH-2501
- FDA Response Letter: The US FDA issued a Complete Response Letter to Lantheus regarding LNTH-2501, stating that the application cannot be approved due to ongoing issues at a third-party manufacturing site, although no issues were noted with the supporting data, indicating the clinical data still holds potential.
- Manufacturing Issues: Lantheus CEO Mary Anne Heinosaid mentioned that the company is working closely with its partner and the FDA to address facility-related conditions, demonstrating a proactive approach to resolving the issues and advancing the program.
- Market Reaction: Despite the FDA challenges, Lantheus reiterated its 2026 revenue outlook of $1.4 billion to $1.45 billion, reflecting confidence in future performance, particularly during the transition period for the PYLARIFY TRUVU product.
- Strategic Adjustments: Lantheus showcased its turnaround progress at the Global Healthcare Conference, and despite regulatory hurdles, the company is evaluating potential sale opportunities, indicating its ability to adapt to market changes.
See More
Lantheus Faces FDA Setback for LNTH-2501 NDA Approval
- FDA Complete Response Letter: Lantheus's NDA for LNTH-2501 was not approved by the June 29, 2026 PDUFA date due to unresolved issues at a third-party manufacturing facility, highlighting compliance challenges that could delay market entry.
- No Data Concerns: The CRL did not raise any issues regarding the data submitted or the safety and efficacy of LNTH-2501, indicating that the clinical potential of the product remains recognized, which may bolster confidence for future applications.
- Management Confidence: CEO Mary Anne Heino expressed strong confidence in LNTH-2501 and commitment to resolving manufacturing issues promptly, a positive stance that could help stabilize investor sentiment amid regulatory setbacks.
- Market Impact: The delay in LNTH-2501's launch, as a diagnostic tool for neuroendocrine tumors, may affect Lantheus's market share in an increasingly competitive radiopharmaceutical landscape, emphasizing the need for swift resolution of regulatory hurdles.
See More
Lantheus Holdings Stock Surpasses Analyst Target Price
- Price Target Surpassed: Lantheus Holdings Inc (Ticker: LNTH) shares have surpassed the average analyst 12-month target price of $105.17, currently trading at $106.20, indicating optimistic market sentiment regarding the company's prospects.
- Diverse Analyst Reactions: Among the 12 analysts covered by Zacks, target prices range from $76.00 to $117.00, with a standard deviation of $11.892, reflecting varying perspectives on the company's valuation that could influence investor decisions.
- Clear Investor Signal: The stock's rise above the average target price provides a strong signal for investors to reassess the company, prompting them to consider whether the current valuation is justified or if it’s time to take profits.
- Wisdom of the Crowd: The average analyst target price embodies the
See More
Lantheus to Speak at Growth Stock Conference
- Conference Participation: John Wiggins, Vice President of External Manufacturing at Lantheus Holdings, will participate in a fireside chat at the William Blair 46th Annual Growth Stock Conference on June 3, showcasing the company's leadership in the radiopharmaceutical sector.
- Live Webcast: The live session is scheduled to begin at 12:10 p.m. ET, allowing investors to access the presentation through the Investors section of the company's website, ensuring transparent communication of key information.
- Replay Availability: A replay of the webcast will be available on the company's website for at least 30 days post-event, providing crucial insights for investors who cannot attend live, thereby enhancing investor relations.
- Company Background: Lantheus has been dedicated to radiopharmaceutical solutions for 70 years, focusing on enabling clinicians to Find, Fight, and Follow disease, ultimately improving patient outcomes.
See More
Lantheus Weighs Sale Following $7 Billion Curium Offer
- Acquisition Proposal: Lantheus Holdings is considering a takeover offer from Curium Pharma valued at approximately $7 billion, indicating strong market interest in its nuclear medicine business and potentially prompting a strategic overhaul.
- Negotiation Progress: The two companies are in discussions about a potential deal that could materialize in weeks, although no final decision has been made, reflecting uncertainty about Lantheus's future in the market.
- Market Reaction: Lantheus shares fell nearly 2% in after-hours trading, yet they have surged 54.8% this year, indicating investor confidence in its long-term growth potential despite short-term volatility.
- Valuation Insight: With a current market capitalization of about $6.15 billion, the acquisition proposal's valuation underscores Lantheus's competitiveness in the radiopharmaceutical sector, potentially attracting further investor interest in its future trajectory.
See More
